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introduction: Conditioning regimens preceding allogeneic stem cell transplantation 
(alloSCT) can cause tissue damage and acceleration of the development of graft- 
versus-host disease (GVHD). T-cell-depleted alloSCT with postponed donor lymphocyte 
infusion (DLI) may reduce GVHD, because tissue injury can be restored at the time of 
DLI. In this study, we investigated the presence of tissue injury and inflammation in skin 
during the period of hematologic recovery and immune reconstitution after alloSCT.
Methods: Skin biopsies were immunohistochemically stained for HLA class II, CD1a, 
CD11c, CD40, CD54, CD68, CD86, CD206, CD3, and CD8. HLA class II-expressing 
cells were characterized as activated T-cells, antigen-presenting cells (APCs), or 
tissue repairing macrophages. In sex-mismatched patient and donor couples, origin 
of cells was determined by multiplex analysis combining XY-FISH and fluorescent 
immunohistochemistry.
results: No inflammatory environment due to pretransplant conditioning was detected 
at the time of alloSCT, irrespective of the conditioning regimen. An increase in HLA class 
II-positive macrophages and CD3 T-cells was observed 12–24 weeks after myeloablative 
alloSCT, but these macrophages did not show signs of interaction with the co-localized 
T-cells. In contrast, during GVHD, an increase in HLA class II-expressing cells coinciding 
with T-cell interaction was observed, resulting in an overt inflammatory reaction with 
the presence of activated APC, activated donor T-cells, and localized upregulation of 
HLA class II expression on epidermal cells. In the absence of GVHD, patient derived 
macrophages were gradually replaced by donor-derived macrophages although patient- 
derived macrophages were detectable even 24 weeks after alloSCT.
conclusion: Conditioning regimens cause tissue damage in the skin, but this does not 
result in a local increase of activated APC. In contrast to the inflamed situation in GVHD, 
when interaction takes place between activated APC and donor T-cells, the tissue 
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inTrODUcTiOn
After allogeneic stem cell transplantation (alloSCT), severe graft-
versus-host disease (GVHD) can be induced by donor T-cells 
recognizing normal tissues of the recipient. T-cell depletion (TCD) 
of the stem cell graft is an effective strategy to prevent GVHD, 
and alloSCT regimens using the CD52 antibody alemtuzumab 
for TCD or using infusion of purified CD34 cells demonstrate 
efficient engraftment and reduced acute GVHD (1–4). Since 
graft-versus-tumor reactivity is reduced after TCD alloSCT, post- 
poned donor lymphocyte infusions (DLIs) are frequently admini-
stered after transplantation to promote antitumor reactivity with 
a lower risk of GVHD (2, 5–7). Reduced incidence of GVHD 
after TCD alloSCT with postponed DLI may partly be explained 
by gradual repair in time of the tissue damage caused by the 
pretransplant conditioning regimen. Tissue damage can accele-
rate the development of acute GVHD by causing release of pro-
inflammatory cytokines such as TNF-α, IL-1β, and IL-6. These 
danger signals can activate host or donor antigen-presenting cells 
(APCs) that in turn present alloantigens to donor T-cells, which 
can activate and amplify alloreactive donor T-cell responses (8). 
Although tissue damage may be restored at the time of postponed 
DLI, GVHD after DLI applied 3–6 months after alloSCT is not 
uncommon (9). Furthermore, although CD4 T-cells recognize 
peptides presented in HLA class II molecules and HLA class II 
is only expressed on non-hematopoietic cells under inflamma-
tory conditions, infusion of purified donor CD4 T-cells 3 months 
after TCD alloSCT with an HLA 10/10 matched, but HLA-DP 
mismatched donor can also result in severe GVHD caused by 
CD4 T-cells directed against the mismatched HLA-DP molecule 
from the patient (10). These findings suggest that, as a result of 
tissue damage after the conditioning regimen, even several 
months after alloSCT, activated APCs of patient origin may still 
be present in target tissues like skin, which may result in the initi-
ation of an alloreactive T-cell response causing GVHD.
In this study, we investigated the hypothesis that activated 
APCs are present for several months in the skin due to tissue 
damage caused by the conditioning regimen given before 
alloSCT. Since beside the conditioning regimen, T-cells admin-
istered at the time of alloSCT can contribute to inflammation 
with the presence of activated APC due to GVHD or immune 
responses against pathogens, it is not possible to investigate this 
hypothesis after T-cell replete alloSCT. Therefore, we investigated 
the presence of activated APC in the skin in the absence of an 
alloimmune response at several time points after TCD alloSCT. 
We illustrate that there is no increase in HLA class II-positive 
cells or T-cell influx at the time of alloSCT, regardless of the type 
of conditioning regimen. Total body irradiation (TBI) contain- 
ing myeloablative (MA) conditioning, but not non-myeloablative 
(NMA) conditioning or conditioning preceding autologous stem 
cell transplantation (autoSCT), resulted in dermal recru it ment 
of HLA class II-positive tissue repairing macrophages, most 
prominent in the period of immune reconstitution 12–24 weeks 
after alloSCT with co-localization of T-cells, but without inflam-
matory interaction. In the absence of an alloimmune response, 
as expected, the percentage of HLA class II-positive dermal 
macrophages of recipient origin decreased gradually over time 
after alloSCT, while percentage of HLA class II-positive dermal 
macrophages from donor origin increased.
MaTerials anD MeThODs
Patients
After approval by the LUMC Institutional Review Board and 
written informed consent from the patient according to the 
Declaration of Helsinki, a 4-mm punch biopsy from normal skin 
over the posterior iliac crest was taken from patients at the day 
of alloSCT or at 3, 6, 12, or 24 weeks after alloSCT in the absence 
of GVHD. In case of the presence of GVHD after alloSCT, a skin 
biopsy was taken from affected skin. Diagnosis of skin GVHD 
was confirmed by an experienced pathologist.
The NMA conditioning regimen preceding HLA identical 
alloSCT consisted of fludarabine (50 mg/m2 orally from days −10 
to −5), busulfan (0.8  mg/kg iv four times a day on days −7 
and −6), and alemtuzumab (15 mg iv on days −4 and −3). In case 
of a matched unrelated donor (MUD), patients were also treated 
with antithymocyte globulin (thymoglobulin, 1 mg/kg on day −2). 
MA conditioning consisted of cyclophosphamide (60  mg/kg 
iv on days −6 and −5) and TBI (9 Gy on day −1) in case of an HLA 
identical sibling donor. In case of an MUD, alemtuzumab (15 mg 
on days −5 and −6) and cyclosporine A (starting 1.5  mg/kg 
twice a day with tapering to 0 in 3 months) was given as GVHD 
prophylaxis. Stem cell grafts were T-cell depleted by addition of 
20 mg alemtuzumab to the bag before administration (2, 11).
Skin biopsies were taken from patients at different time points 
after autoSCT, from healthy donors, and from affected skin of 
patients suffering dermatitis medicamentosa and were used as 
controls for the effect of chemotherapeutic conditioning in the 
absence of a potential allogeneic immune response, the normal 
situation, or an inflamed environment, respectively. The auto- 
SCT conditioning regimen consisted of high-dose melphalan 
100  mg/m2 for 2  days for patients with multiple myeloma and 
BEAM (BCNU 300 mg/m2, cytosine arabinoside 100 mg/m2 twice 
damage caused by myeloablative alloSCT results in dermal recruitment of HLA class 
II-positive tissue repairing macrophages co-existing with increased numbers of patient- 
and donor-derived T-cells, but without signs of specific interaction and initiation of an 
immune response. Thus, the local skin damage caused by the conditioning regimen 
appears to be insufficient as single factor to provoke GVHD induction.
Keywords: hla class ii, tissue damage, allogeneic stem cell transplantation, graft-versus-host disease, 
macrophages, skin
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daily for 4 days, etoposide 100 mg/m2 twice daily for 4 days, and 
melphalan 140 mg/m2) for patients with non-Hodgkin lymphoma. 
Waste material after cosmetic surgery was used for biopsies 
from healthy controls.
All skin biopsy samples were sharp dissected and snap-frozen 
on Tissue-Tek (Sakura Finetek, Alphen a/d Rijn, Netherlands) in 
cooled iso-pentane (Sigma Aldrich, Zwijndrecht, Netherlands) 
and cryopreserved at −80°C. Tissues obtained from controls and 
patients with GVHD were also fixed in 10% v/v formalin and 
embedded in paraffin. Total numbers of biopsy samples included 
in the study as well as basic patient characteristics are listed in 
Table S1 in Supplementary Material.
immunofluorescence labeling of  
skin Biopsies
To investigate the pro-inflammatory environment in the skin at 
various time points after transplantation, 4-µm cryopreserved 
sections were cut, dried for 1 h at 60°C followed by 30 min at 
room temperature, and fixated in acetone for 10 min. Immuno-
histochemical staining was performed overnight at room tem-
perature using monoclonal antibodies (MoAbs) against CD3 
(IgG2a, Ps1-ab699, Abcam, Cambridge, MA, USA) and CD8 
(IgG2b, 4B11, Leica Microsystems, Rijswijk, Netherlands) as 
markers for T-cell infiltration in the skin and against HLA class II 
(IgG1, p104630, Dako, Heverlee, Belgium), HLA-DR (IgG2b, 
B8.11.2), and CD54 (IgG1, ab20, Abcam) as markers for activa- 
ted cells. To investigate whether HLA class II-positive cells in 
skin biopsies were resident dermal dendritic cells (DCs), inflam-
matory dermal DC, or dermal macrophages, staining with MoAb 
against CD1c (IgG1, MCA694, Bio-Rad Laboratories, Veenendaal, 
Netherlands), CD11c (IgG1, B-Ly6, BD, Breda, Netherlands), 
CD40 (IgG1, 5C3, BD), CD54 (IgG1, ab20, Abcam), CD86 (IgG1, 
ab23556, Abcam), CD206 (IgG1, 19.2, BD), and CD209 (IgG1, 
AZM D1, BD) was performed. Afterward, slides were incubated 
for 1 h at room temperature with secondary fluorescently labeled 
goat-anti-mouse IgG2a ALEXA 546 (red), IgG2b ALEXA 
647 (blue), and IgG1 ALEXA 488 (green) (Alexa, Invitrogen, 
Breda, Netherlands) diluted in phosphate-buffered saline with 
1% bovine serum albumin. After washing, slides were covered 
with Mowiol 4-88 (Sigma Aldrich), and images were captured by 
confocal laser scanning microscope LSM510 (Zeiss, Sliedrecht, 
Netherlands).
To investigate whether cells were of patient or donor origin, 
XY-FISH was combined with surface immunofluorescent stain- 
ing for biopsies taken from patients who had undergone a 
sex-mismatched transplantation. Directly after primary surface 
staining with CD3 or HLA-DR antibodies and secondary stain-
ing with the ALEXA antibodies, slides were digested for 3 min at 
37°C with a pepsin solution (Dako; Code K5799) washed with 
PBS and postfixed with PBS containing 1% formaldehyde. After 
washing in PBS and dehydration in descending ethanol series, the 
slides were air dried. Subsequently, 10 µl probe mix containing 
CEP X (DXZ1) SpectrumGreen/CEP Y (DYZ3) SpectrumOrange 
(Abbot, Hoofddorp, Netherlands) was pipetted onto the slides, 
and denaturation was performed for 3 min at 80°C. Hybridiza- 
tion was performed overnight in a humid chamber at 37°C and 
after two washing steps (SCC/0.05% Tween and 0.4× SCC at 
72°C for 3 min) and dehydration, slides were coverslipped with 
vectashield containing a nuclear stain (DAPI).
Images were captured with a confocal laser scanning micro-
scope (LSM700, Zeiss) in a multitrack setting and analyzed with 
the LSM700 software.
statistical analysis
Quantification of labeled cells in the dermis was done using 
Image J (National Institutes of Health, Bethesda, MD, USA) by 
measuring the dermal area count, which is a calculation of 
the percentage of the area taken by the labeled cells as a part 
of the total dermal area in the biopsy as described before (12). 
Computer-assisted calculations were done to estimate the per- 
centage of colored area in respect to the total area of a part 
of the biopsy. Dermal area count of at least two fields of 
521µm × 521 µm per biopsy was measured. Only labeled cells 
in the dermis were counted, and labeled cells in the epidermis 
were excluded from the calculation. Mean dermal area counts 
of HLA class II- and CD3-positive cells in skin biopsies were 
calculated at different time points and conditioning regimens 
after autoSCT, NMA, and MA alloSCT. Kruskal–Wallis test was 
performed to compare median dermal area counts, and in case 
the null hypothesis, being no differences in medians between 
different groups, could be rejected, post  hoc Mann–Whitney 
U-test was performed to compare dermal area counts between 
two specific groups and significance was accepted as p < 0.05.
resUlTs
no Overt inflammatory environment in the 
skin at Time of alloscT
To investigate whether conditioning before alloSCT results in an 
inflammatory environment in the skin coinciding with increased 
expression of HLA class II molecules and attraction of T-cells, 
the quantitative presence of HLA class II- or CD3-expressing 
cells in the dermal layer was substantiated by dermal area count 
calculation in skin biopsies taken from patients at the time of 
the transplantation following NMA or MA conditioning and 
compared to normal skin biopsies. As shown in a representative 
example in Figure  1A, in normal control skin biopsies, HLA 
class II-expressing cells were present scattered over the dermal 
region and showed mainly a clustering pattern around the vascu-
lar and follicular structures. In the epidermal layer, HLA class II- 
expressing cells were only sporadically observed. In control 
skin biopsies of inflamed skin from patients with dermatitis 
medicamentosa, an increase in HLA class II-expressing cells 
was observed, scattered over the dermal and epidermal layer 
(Figure  1B). Analysis of biopsies taken directly after pretrans-
plant conditioning at the day of transplantation revealed no 
clear increase in the number of HLA class II-expressing cells. 
The scattered pattern of HLA class II-expressing cells strongly 
resembled the situation in normal skin, as illustrated by the 
depicted representative examples for each type of conditioning 
in Figures  1C,D. To substantiate the amount of HLA class II 
expression in the different biopsies, dermal area counts were 
calculated. A significant increase in HLA class II-expressing cells 
FigUre 1 | Pretransplant conditioning did not result in a pro-inflammatory environment in the skin at the time of transplantation. (a) In normal skin, HLA  
class II-expressing cells and also T-cells are present scattered over the whole dermal region. In the epidermal layer, HLA class II-expressing cells were observed 
sporadically. (B) In skin affected by dermatitis medicamentosa, dermal area count of HLA class II-expressing cells and T-cells is higher compared to normal skin. 
After non-myeloablative (NMA) conditioning (c) and myeloablative (MA) conditioning (D), the presence of HLA class II-expressing cells and T-cells at the time of 
allogeneic stem cell transplantation (alloSCT) resembled the situation in normal skin. Dermal area counts with median were calculated for HLA class II-expressing 
cells (e) and CD3 T-cells (F) in skin biopsies of normal skin, skin at the time of alloSCT after NMA and MA conditioning, and skin affected by dermatitis 
medicamentosa. A significant difference was detected regarding HLA class II-expressing cells between normal skin and skin affected by dermatitis  
medicamentosa (Kruskal–Wallis test p = 0.019, post hoc Mann–Whitney U-test p = 0.016). White line demarks the border between dermis and epidermis.
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was observed in skin biopsies of dermatitis medicamentosa 
compared to normal skin (Kruskal–Wallis test p = 0.019, post hoc 
Mann–Whitney U-test p = 0.016). HLA class II-expressing cells 
were not increased in biopsies taken at the day of transplant 
after NMA or MA conditioning (Figure 1E).
In normal skin, both CD4 (defined as CD3-positive CD8-
negative cells) and CD8 T-cells were found scattered over the der-
mis without signs of clustering or co-expression of HLA class II 
(Figure  1A), indicating a non-activated status of these T-cells. 
In case of dermatitis medicamentosa, an increase in T-cells 
(Kruskal–Wallis test p = 0.058) was observed in some, but not 
in all biopsies (Figures 1B,F). These T-cells were not activated as 
illustrated by the lack of co-expression of HLA class II molecules. 
No significant increase in the percentages of T-cells in the skin at 
the day of transplantation was observed, irrespective of the type 
of conditioning (Figure 1F). These data show that neither NMA 
nor MA conditioning regimen resulted in increased numbers 
of HLA class II-expressing cells or attraction of T-cells in the 
skin at the day of alloSCT.
increase of hla class ii-Positive cells  
in skin Biopsies 12–24 Weeks after  
Ma alloscT
To analyze the activation status of dermal cells early after allo-
SCT and after hematopoietic reconstitution in the absence of an 
allogeneic immune response, we substantiated the amount of 
HLA class II-expressing cells and T-cells in skin biopsies taken 
during hematopoietic recovery (3 and 6 weeks after transplanta-
tion) and during the period of immune reconstitution (12 and 
24 weeks after transplantation) by dermal area count calculation. 
Patients were selected not to have GVHD of the skin. Biopsies 
taken at various time points after transplantation were compared 
to biopsies taken at the day of transplantation (T = 0). Biopsies 
taken from patients treated with autoSCT following intensive 
chemotherapy conditioning served as a control to determine the 
possible influence of an alloreactive T-cell response.
In the skin biopsies taken after autoSCT, no increase in HLA 
class II-expressing cells or T-cells was observed within the first 24 
week after transplantation (Figures 2A,B). No increase in HLA 
class II-expressing cells or CD3 T-cells was found after NMA 
alloSCT (Figures 2C,D). In contrast, after MA alloSCT, a signifi-
cant increase (p = 0.020, Kruskal–Wallis test) in HLA class II- 
expressing cells in the dermis was observed from median 2.1% of 
dermal region at the time of alloSCT to 12.9% at 12 weeks after 
alloSCT (p = 0.03, post hoc Mann–Whitney U-test) and to 16.5% 
at 24 weeks after alloSCT (p = 0.008, post hoc Mann–Whitney 
U-test) (Figure 2E). In addition, the numbers of T-cells appeared 
to increase within the first 24  weeks after MA alloSCT from a 
median of 0.83% of the dermal region at time of alloSCT to 4.6% 
at 24 weeks after alloSCT, although this increase did not reach 
statistical significance (p = 0.12, Kruskal–Wallis test) (Figure 2F). 
FigUre 2 | Remarkable increase in HLA class II-expressing cells after myeloablative (MA) allogeneic stem cell transplantation (alloSCT). Calculated dermal area 
counts with medians are depicted. No increase in HLA class II-expressing cells (a) or T-cells (B) was observed after autoSCT. Also, no increase in HLA class 
II-expressing cells (c) or T-cells (D) was observed after non-myeloablative (NMA) alloSCT. In contrast, following MA, alloSCT there was a significant increase in HLA 
class II-expressing cells after 12 and 24 weeks compared to T = 0 (Kruskal–Wallis test p = 0.020 and post hoc Mann–Whitney U-test p = 0.03 and 0.008)  
(e) and a non-significant increase in T-cells after 24 weeks (Kruskal–Wallis test p = 0.12) (F). (g–i) Results of fluorescence microscopy of illustrative examples 
showing HLA class II- and CD3-expressing cells 24 weeks after autologous (g), NMA (h), or MA (i) transplantation. White line demarks the border between dermis 
and epidermis.
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The immunofluorescence microscopic pictures in Figures 2G–I 
illustrate the presence of HLA class II-expressing cells and CD3 
T-cells in biopsies taken 24 weeks after autoSCT, NMA, and MA 
alloSCT, respectively.
These data illustrate that after NMA alloSCT, in the absence 
of GVHD, no change in numbers of HLA class II-expressing cells 
or CD3 cells occurred. However, 12–24 weeks after MA alloSCT, 
despite the absence of any sign of GVHD, there was a significant 
increase in HLA class II-positive cells in the dermal region of 
the skin as well as an increase in T-cells after 24 weeks. Despite 
this increase, no signs of inflammation or interaction between the 
HLA class II-positive cells and the T-cells were detected, because 
T-cells appeared not to be activated illustrated by the lack of 
expression of HLA class II.
Massive inflammation in Biopsies  
of acute skin gVhD
To investigate whether the skin biopsies that showed significant 
increase in HLA class II-positive cells 24 weeks after MA alloSCT 
were immunohistochemically different from biopsies with overt 
inflammation, skin biopsies taken from patients suffering from 
acute skin GVHD within 24 weeks after alloSCT were analyzed.
Dermal area counts of HLA class II-expressing cells and CD3 
T-cells were not significantly different in biopsies taken from 
FigUre 3 | Biopsies from patients with acute skin graft-versus-host disease (GVHD) showed massive inflammation. Both dermal area count (excluding by definition 
the epidermal area count) of HLA class II-positive cells (a) and CD3-positive cells (B) were not significantly different between biopsies taken during acute skin GVHD 
and biopsies of normal skin taken 24 weeks after myeloablative (MA) allogeneic stem cell transplantation (alloSCT). However, immunofluorescence microscopy 
showed honeycomb pattern of HLA class II expression on epidermal cells and upregulation of HLA class II expression on T-cells (yellow hued cells) during GVHD as 
signs of inflammation (c), while in normal skin biopsies 24 weeks after MA alloSCT, co-localization of HLA class II-positive cells and T-cells without interaction was 
observed (D). Pink hued cells represent CD8-positive CD3 T-cells. White line demarks the border between dermis and epidermis.
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patients during acute skin GVHD compared to biopsies taken 
from patients without GVHD 24  weeks after MA alloSCT 
(Figures 3A,B). Of note, the epidermal area was excluded in 
the dermal area count calculations. However, major differ-
ences were observed between biopsies taken during GVHD or 
24  weeks after MA alloSCT in the absence of GVHD. First, 
in biopsies taken from affected skin during GVHD, localized 
induction of HLA class II expression in a honeycomb pattern 
became visible in the epidermal layer (Figure  3C), illustrat-
ing upregulation of HLA class II expression on epidermal 
keratinocytes as a result of inflammation. This phenomenon 
was not observed in skin without GVHD where the presence 
of HLA class II-positive cells remained limited to the dermal 
region (Figure  3D). Second, in GVHD biopsies, the T-cells 
showed overt upregulation of HLA class II expression, illus-
trating activation of these T-cells. Skin without GVHD showed 
an increase in both HLA class II-positive cells and T-cells, but 
without signs of interaction or upregulation of HLA class II 
expression on the T-cells, indicating that the HLA class II- 
expressing cells did not function as APCs for the T-cells present 
(Figures 3C,D).
These data show that in biopsies of skin affected by GVHD, 
massive inflammation is present, while the observed increase 
in HLA class II-positive cells during the immune reconstitu-
tion period after MA alloSCT is rather co-localization of HLA 
class II-positive cells with T-cells without signs of interaction or 
inflammation.
recruitment of Macrophages, rather  
than activated aPc, caused the  
increase in hla class ii-expressing  
cells after Ma alloscT
To determine the nature of the increased numbers of HLA class 
II-positive cells observed in the dermal region of the skin during 
immune reconstitution following MA transplantation, expres-
sion of CD1c, CD11c, CD40, CD54, CD86, and CD206 (mannose 
receptor) was measured, since these markers allow distinction of 
different subsets of dermal APC (Table 1) (13–16). Biopsies of 
normal skin (n =  2), skin 24 weeks after MA alloSCT (n =  5) 
and skin affected by GVHD (n = 4) were analyzed. The majority 
of HLA class II-expressing cells in normal skin was found to be 
macrophages, as indicated by the expression of CD68 on HLA 
class II-positive cells and expression of CD206 on HLA class II- 
positive cells, while also resident dermal DCs (CD11c and HLA 
class II-positive) could be detected. The HLA class II-positive 
cells did not show expression of costimulatory markers such as 
CD40, CD54, or CD86 (Figure 4A). Similar to normal skin, the 
majority of HLA class II-expressing cells found in skin biopsies 
taken after MA alloSCT in the absence of GVHD appeared to be 
macrophages (HLA class II-positive cells were expressing CD68- 
and HLA class II-positive cells were expressing CD206) (Figure 4B) 
that did not harbor the phenotype of resident or inflammatory 
dermal DCs illustrated by the absence of CD11c expression. This 
observation was identical for the HLA class II-positive cells found 
TaBle 1 | Phenotype of different dermal antigen-presenting cells.
antigen-presenting cell immunophenotype
Resident dermal DC HLA-DR+, CD11c+, CD1c+, CD14−
Inflammatory dermal DC HLA-DR+, CD11c+, CD1c−, CD14−, CD40+, 
CD54+, CD86+
Dermal macrophages HLA-DR+, CD14+, CD68+, CD206+, CD163+
DC, dendritic cell; CD54, ICAM-1; CD206, mannose receptor.
FigUre 4 | Dermal HLA class II-expressing cells seen after myeloablative (MA) allogeneic stem cell transplantation (alloSCT) were macrophages with  
non-professional antigen-presenting cell (APC) phenotype. (a) In normal skin, the majority of HLA class II-expressing cells were macrophages, as indicated  
by the expression of CD68 and CD206, while also some resident dermal dendritic cells (CD11c positive) were detected. The HLA class II-expressing cells were 
negative for CD40, CD54, and CD86. (B) Skin biopsies taken from patients in which an increase in HLA class II-positive cells was observed after MA alloSCT.  
HLA class II-expressing cells were CD68- and CD206-positive macrophages from which only a few expressed also CD11c. There was no expression of CD40, 
CD54, or CD86, so the HLA class II-expressing cells did not have the characteristics of activated professional APC. (c) Skin biopsies from skin affected by acute 
graft-versus-host disease (GVHD) showed increase in HLA class II-expressing cells with professional inflammatory APC phenotype (CD11c, CD40, CD54, and  
CD86 positive, while CD206 is negative). White line demarks the border between dermis and epidermis.
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in skin of patients irrespective of the conditioning regimen and 
time point after transplantation. In accordance, these HLA class 
II-positive cells did not express costimulatory molecules CD40, 
CD54, or CD86 (Figure 4B).
In contrast, in biopsies from inflamed skin taken during acute 
GVHD, the increase in HLA class II-expressing cells was not cau-
sed by macrophages, but by an increase in inflammatory DCs, 
because HLA class II-positive cells expressed CD11c, CD40, 
CD54, and CD86 in separate stainings (Figure 4C).
These data illustrate that during the immune reconstitution 
period 12–24 weeks after MA alloSCT, in the absence of acute 
GVHD, the observed increase in HLA class II-expressing cells 
in the dermis was caused by dermal macrophages with a non-
professional APC phenotype. In contrast, in biopsies taken at the 
time of acute GVHD, inflammatory dermal DCs with profes-
sional APC phenotype were present.
gradual replacement of recipient 
Macrophages by Donor Macrophages
To investigate whether the observed dermal macrophages with 
non-professional APC phenotype after alloSCT were of patient 
or donor origin, XY-FISH combined with staining of HLA class II 
was performed after alloSCT from patients with a gender- 
mismatched donor. Skin biopsies taken from patients after auto- 
SCT were used as negative controls. After alloSCT, a gradual 
decline of the percentages of patient-derived HLA class II-positive 
cells was observed, and HLA class II-positive cells of patient ori- 
gin were replaced by cells of donor origin. However, even 24 weeks 
after alloSCT, HLA class II-positive cells of patient origin could 
be detected in the skin (Figures 5A–C). In the first 3–6 weeks 
after transplantation, in the absence of GVHD dermal T-cells 
were found to be predominantly of patient origin, whereas from 
12 weeks after transplantation, a mixture of patient- and donor-
derived T-cells was found. As expected, biopsies taken from the 
affected skin during active GVHD showed massive infiltration of 
donor T-cells (Figures 5D–F).
These data illustrate that early after transplantation, in the 
absence of an alloreactive immune response, the majority of HLA 
FigUre 5 | Gradual replacement of cells from recipient origin by cells of donor origin. (a) Percentage of recipient origin HLA class II-positive cells in the skin 
declined over time after allogeneic stem cell transplantation (alloSCT), but remained present even after 24 weeks. After autologous stem cell transplantation 
(autoSCT), no mixed chimera were observed, and in biopsies taken at the time of graft-versus-host disease (GVHD), the majority of HLA class II-positive cells were 
from donor origin. (B) Skin biopsy taken 3 weeks after alloSCT from a male patient with a female donor. All epithelial cells were XY, and nearly all HLA class 
II-positive cells were XY although some HLA class II-positive cells were XX (white arrows). (c) Skin biopsy taken 24 weeks after alloSCT from a male patient with a 
female donor. All epithelial cells were XY and all HLA class II-positive cells in this part of the biopsy were XX (white arrows). (D) Big differences were observed in the 
skin biopsies regarding the chimerism of CD3-positive cells. (e) 3 weeks after alloSCT, nearly all CD3-positive cells were from patient origin, except those indicated 
with a white arrow (male patient with female donor). (F) At the time of GVHD all CD3-positive cells were from donor origin (infiltrate of male donor CD3-positive cells 
in the skin of a female patient). White line demarks the border between dermis and epidermis.
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class II-positive cells were of patient origin, whereas late after 
transplantation, the majority of HLA class II-positive cells were 
of donor origin, illustrating the gradual replacement of patient 
macrophages by donor macrophages.
DiscUssiOn
Our data illustrate that the conditioning regimen before alloSCT 
did not directly cause an inflammatory environment in the skin 
at the day of infusion of the stem cell graft. In the absence of 
GVHD, after hematologic recovery following TBI containing MA 
alloSCT, HLA class II-positive macrophages, but not cells with 
a phenotype of professional APC were recruited to the dermal 
region of the skin. These HLA class II-positive macrophages 
are most probably involved in repairing tissue damage. T-cells 
were also recruited to the dermal area, but did not show acti-
vation or interaction with the HLA class II-positive cells. In 
contrast, after conditioning regimens lacking TBI, no increase in 
dermal macrophages or T-cells was observed during the phase 
of hematologic and immunologic recovery. In the absence of 
GVHD, patient chimerism of dermal HLA class II-positive cells 
gradually changed over time to a median of 23% at 6  months 
after alloSCT, but patient-derived HLA class II-positive cells 
remained detectable. Skin affected by GVHD also contained 
high number of T-cells and HLA class II-expressing cells, but with 
an activated APC phenotype. In these biopsies, strong interac-
tions between APC and T-cells were seen, coincided by the acti-
vation of T-cells and local inflammation resulting in upregulation 
of HLA class II molecules also on epidermal cells. Probably due 
to destruction of recipient-derived APC by donor T-cells during 
GVHD, these biopsies only contained APC of donor origin.
Although in concordance with previous studies, which illus-
trated HLA class II expression in skin biopsies after alloSCT in 
the absence of GVHD and T-cells infiltrating the skin with 
upregulation of HLA class II on non-hematopoietic cells occur-
ring during GVHD (17, 18), our findings give novel insights. 
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First, the HLA class II-positive cells detected after alloSCT in the 
absence of GVHD turned out not to be APC, but macrophages. 
High expression of CD206 on HLA class II-positive cells was 
found, which is predominantly present on macrophages playing 
a role in later stages of tissue repair in the skin and in the remod-
eling phase (19). Second, an increase in T-cells after MA alloSCT 
in the absence of GVHD was observed without inflammation 
or interaction with the HLA class II-positive cells. This may be 
explained by the presence of regulatory T-cells or γδ T-cells 
known to be involved in tissue repair or T-cells present for the 
purpose of immune surveillance (20, 21). We observed an increase 
in tissue repairing macrophages only after TBI containing MA 
and not after other conditioning regimens, indicating that TBI 
probably is the main contributor to the tissue damage. Although 
no inflammation or interaction between macrophages and T-cells 
was observed after MA alloSCT in the absence of GVHD, the 
increased presence of HLA class II-positive macrophages may 
result in higher susceptibility to an immune response in case 
subsequent DLI is administered.
After initial profound TCD, relatively high-dose DLI is requi-
red from 6 months after alloSCT to induce GVHD. In contrast, 
infusion of a tenfold lower dose after 3  months has already a 
significant risk of induction of GVHD (7, 9). It has been hypo-
thesized that, due to tissue damage caused by the conditioning 
regimen, an inflammatory environment with activated APC in 
the skin during the hematologic and immunologic reconstitution 
would be the primary initiation of this response. However, our 
results illustrate that tissue damage is unlikely to be sufficient to 
create an environment for induction of an alloreactive immune 
response. Although tissue damage can result in the release of 
cytokines, this does not result in costimulatory molecule ex- 
pressing activated APC able to appropriate present recipient-
derived antigens to donor T-cells. This is in concordance with 
previous findings that, under non-inflammatory conditions, non- 
hematopoietic tissues are not highly susceptible to GVHD reac-
tivity of alloreactive T-cells due to their inability to establish high 
avidity interactions (22).
Despite the lack of activated APC in the skin, there are sev-
eral other explanations for the observed occurrence of GVHD 
induced by postponed application of DLI 3–6  months after 
TCD alloSCT. First, the alloreactive immune response can be 
initiated in interaction with activated APC outside the skin, 
followed by the release of an abundance of T-cell stimulating 
cytokines, upregulation of costimulatory molecules on APC and 
amplification of the immune response in the skin. Alternatively, 
an immune response to viral or bacterial infections can result 
in the cascade of events inducing an immune response with 
coinciding GVHD (10, 23, 24). Furthermore, if there is an HLA 
class II mismatch between patient and donor, macrophages in 
the skin, expressing this mismatched HLA, can be recognized by 
allo-HLA class II reactive donor CD4 T-cells (10, 25). Although 
for the initiation of an alloreactive immune response from naive 
donor T-cells APC are required, memory donor T-cells directed 
against a mismatched HLA class II molecule do not need acti- 
vation by APC. We previously demonstrated the occurrence of 
skin GVHD after the infusion of purified donor CD4 T-cells 
3 months after transplantation in patients who are HLA 10/10 
matched but mismatched compared to their donor regarding 
HLA-DP (10).
The results of our study illustrate that there is a gradual 
replacement of patient macrophages in the skin by donor mac-
rophages, which is concordant with previous findings by others 
(26). The observation that HLA class II-positive macrophages 
of patient origin remain present in the skin for at least 6 months 
after alloSCT has to be taken into account in the risk assessment 
of administration of DLI post alloSCT, especially in the admi-
nistration of donor T-cells in case of an HLA class II mismatch 
between patient and donor.
In summary, after NMA conditioning, there is no increase in 
HLA class II-positive cells and T-cells in the skin. TBI contain-
ing MA conditioning results in a significant increase in HLA 
class II-positive macrophages without APC phenotype and an 
increase in T-cells without activation, in the absence of interaction 
with each other. It is unlikely that these cells can directly initiate 
an alloreactive immune response in the skin. If there is an HLA 
class II mismatch between patient and donor, dermal mac-
rophages may be responsible for the induction of an immune 
response by memory T-cells in the skin. Otherwise, initiation 
of an alloreactive immune response is likely to be dependent on 
primary events outside of the skin.
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